Ocumension Therapeutics
5DG
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
552
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,404.70 | 0.80 | -0.01% |
| CAC 40 | 8,694.86 | 20.08 | -0.23% |
| DAX 40 | 26,490.33 | 98.91 | 0.37% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,840.26 | 3.93 | -0.04% |
| HKSE | 25,440.17 | 212.65 | -0.83% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 67,524.06 | 553.84 | 0.83% |
| NZX 50 Index | 13,737.66 | 123.00 | -0.89% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,209.40 | 2.20 | -0.02% |
| SSE Composite Index | 3,946.68 | 12.58 | 0.32% |